BCMA-directed T cell therapy optimization in multiple myeloma
Official title: preclinical optimization of BCMA directed T cell therapy
Funded at Mayo Clinic Arizona · NIH-11394636 · Data updated 2026-11-12
A Mayo Clinic team is testing improved, immune-based BCMA therapy to help people with multiple myeloma when current treatments fail.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $621,878 |
| NIH project number | 5R01CA272426-04 |
| Project ID | NIH-11394636 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not a patient-facing trial; results could influence future treatments for adults with multiple myeloma.
✕Less likely to help
Individual patients are not enrolled in this preclinical study; findings may inform future clinical approaches.
What this research studies
This project uses a fully immunocompetent mouse model that mimics human multiple myeloma to study how BCMA-targeted T cell therapies interact with the tumor and immune environment. The researchers will test combinations that could boost T cell function and improve the effectiveness of bispecific antibodies against BCMA. By understanding how tumor burden and immune interactions affect therapy, they aim to identify strategies that translate to better responses in patients. The work focuses on preclinical studies to guide future clinical approaches, rather than immediate patient treatment. The ultimate goal is to inform more durable, effective immunotherapies for multiple myeloma patients.
Why it matters
Potential benefit: If successful, this research could guide the design of more effective BCMA-based immunotherapies for myeloma patients, potentially leading to longer-lasting remissions.
How similar studies have gone: Preclinical models have shown that immune interactions and tumor burden influence bispecific antibody activity; this work builds on that knowledge in a more clinically predictive setting.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Chesi, Marta — Mayo Clinic Arizona
- Study coordinator: Chesi, Marta
Related research
Other NIH-funded projects on the same topics.
-
Predicting Pain Recovery with a Multimodal AI using Harmonized Health Records
Aging patients with headaches will be helped by a new AI tool that uses medical records and brain images from Mayo Clinic and VA to predict who might have persistent pain.
-
Understanding immune signals in ALS to guide future therapies
A Mayo Clinic team will study how the immune system sees proteins in the brain of people with ALS and related conditions, to find clues for better treatments.
-
Determinants of Pathogenic Anti-PF4 Antibody–Mediated Platelet Activation
This project looks at why certain anti-PF4 antibodies in people cause harmful blood clots and how to better diagnose and treat those cases.
-
Understanding how a type of immune cell called ILC2s affect asthma in adults
This grant studies how group 2 innate lymphoid cells influence asthma in adults to help identify new ways to manage airway inflammation.
-
EHMT1 Variants and Kleefstra Syndrome: How Structure Shapes Neurodevelopmental Risks
A small NIH grant will explore how genetic changes in EHMT1 affect brain development in Kleefstra Syndrome using computer models and analysis of protein structure.
-
Targeting epigenomic regulators to assault pancreatic cancer replication stress
This research tests a new way to treat pancreatic cancer by blocking key epigenetic regulators during DNA replication to make cancer cells less able to cope with replication stress.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.